Based on OPSL technology, Genesis CX lasers feature outstanding reliability and performance. Wavelengths range from 355 nm to 577 nm and power scales from tens of milliwatts to 10 Watts, allowing these OPSLs to be tailored to the needs of your specific application.
The Genesis CX STM-Series is a single transverse mode, TEM00 is intended for life sciences and research application, and is available at several wavelengths from 355 nm to 577 nm, with up to 10W of output power.
The Genesis CX SLM-Series is a single longitudinal mode, TEM00 is intended for single frequency, interferometric applications, and is available at wavelengths ranging from 355 nm to 577 nm with up to 4W of output power.
The Genesis CX STM-Series and Genesis CX SLM-Series are CDRH and CE-compliant and are designed for the OEMs or end users with a power supply that comes with or without a front panel interface. The software interfaces with your existing design, or it can be used stand-alone with our graphical user interface. Air-cooling and water-cooling options are also available.
Read and see more below.
Genesis CX STM-Series and Genesis SLM-Series with superior mode quality target applications such as life sciences, research, and holography and interferometry. Genesis CX-Series are available in an OEM configuration as well as with a benchtop controller for end user (front-panel interface) applications.
Coherent has locations across the globe that are available to provide support for any product, service or inquiry.
5100 Patrick Henry Drive
Santa Clara, CA 95054 USA
Please Read Before Continuing
Risk factors: Except for the historical information contained here, many of the matters discussed in this Web site are forward-looking statements, based on expectations at the time they were made, that involve risks and uncertainties that could cause our results to differ materially from those expressed or implied by such statements. These risks are detailed in the “Factors That May Affect Future Results” section of our latest 10-K or 10-Q filing. Coherent assumes no obligation to update these forward-looking statements.